Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem and Pralurbactam for CRE Infections
NCT07089186Phase 3Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pralubactam in hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP), Intra-abdominal infection (IAI), complicated urinary tract infection (cUTI), bloodstream infection (BSI), sponsored by Qilu Pharmaceutical. Started Apr 2025; status: recruiting.
02
Drugs
pralubactam
03
Conditions
hospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)Intra-abdominal infection (IAI)complicated urinary tract infection (cUTI)bloodstream infection (BSI)
Beyond the preview
Go deeper on NCT07089186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07089186.